Trop-2 in Upper Tract Urothelial Carcinoma
Trophoblast cell surface antigen 2 (Trop-2, encoded by <i>TACSTD2</i>) is the target protein of sacituzumab govitecan, a novel antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma. However, the expression status of Trop-2 in upper tract urothelial carcinoma (UT...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/6/312 |
| _version_ | 1797488421513461760 |
|---|---|
| author | Eisuke Tomiyama Kazutoshi Fujita Kosuke Nakano Ken Kuwahara Takafumi Minami Taigo Kato Koji Hatano Atsunari Kawashima Motohide Uemura Tetsuya Takao Hiroaki Fushimi Kotoe Katayama Seiya Imoto Kazuhiro Yoshimura Ryoichi Imamura Hirotsugu Uemura Norio Nonomura |
| author_facet | Eisuke Tomiyama Kazutoshi Fujita Kosuke Nakano Ken Kuwahara Takafumi Minami Taigo Kato Koji Hatano Atsunari Kawashima Motohide Uemura Tetsuya Takao Hiroaki Fushimi Kotoe Katayama Seiya Imoto Kazuhiro Yoshimura Ryoichi Imamura Hirotsugu Uemura Norio Nonomura |
| author_sort | Eisuke Tomiyama |
| collection | DOAJ |
| description | Trophoblast cell surface antigen 2 (Trop-2, encoded by <i>TACSTD2</i>) is the target protein of sacituzumab govitecan, a novel antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma. However, the expression status of Trop-2 in upper tract urothelial carcinoma (UTUC) remains unclear. We performed immunohistochemical analysis of 99 UTUC samples to evaluate the expression status of Trop-2 in patients with UTUC and analyze its association with clinical outcomes. Trop-2 was positive in 94 of the 99 UTUC samples, and high Trop-2 expression was associated with favorable progression-free survival (PFS) and cancer-specific survival (<i>p</i> = 0.0011, 0.0046). Multivariate analysis identified high Trop-2 expression as an independent predictor of favorable PFS (all cases, <i>p</i> = 0.045; high-risk group (pT3≤ or presence of lymphovascular invasion or lymph node metastasis), <i>p</i> = 0.014). Gene expression analysis using RNA sequencing data from 72 UTUC samples demonstrated the association between high <i>TACSTD2</i> expression and favorable PFS (all cases, <i>p</i> = 0.069; high-risk group, <i>p</i> = 0.029). In conclusion, we demonstrated that Trop-2 is widely expressed in UTUC. Although high Trop-2 expression was a favorable prognostic factor in UTUC, its widespread expression suggests that sacituzumab govitecan may be effective for a wide range of UTUC. |
| first_indexed | 2024-03-10T00:01:57Z |
| format | Article |
| id | doaj.art-0a4fb7c503704d7199085de8222c3759 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T00:01:57Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-0a4fb7c503704d7199085de8222c37592023-11-23T16:13:43ZengMDPI AGCurrent Oncology1198-00521718-77292022-05-012963911392110.3390/curroncol29060312Trop-2 in Upper Tract Urothelial CarcinomaEisuke Tomiyama0Kazutoshi Fujita1Kosuke Nakano2Ken Kuwahara3Takafumi Minami4Taigo Kato5Koji Hatano6Atsunari Kawashima7Motohide Uemura8Tetsuya Takao9Hiroaki Fushimi10Kotoe Katayama11Seiya Imoto12Kazuhiro Yoshimura13Ryoichi Imamura14Hirotsugu Uemura15Norio Nonomura16Department of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Urology, Kindai University Faculty of Medicine, Osaka 589-8511, JapanDepartment of Urology, Kindai University Faculty of Medicine, Osaka 589-8511, JapanDepartment of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Urology, Osaka General Medical Center, Osaka 558-8558, JapanDepartment of Pathology, Osaka General Medical Center, Osaka 558-8558, JapanLaboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, JapanLaboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, JapanDepartment of Urology, Kindai University Faculty of Medicine, Osaka 589-8511, JapanDepartment of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Urology, Kindai University Faculty of Medicine, Osaka 589-8511, JapanDepartment of Urology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanTrophoblast cell surface antigen 2 (Trop-2, encoded by <i>TACSTD2</i>) is the target protein of sacituzumab govitecan, a novel antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma. However, the expression status of Trop-2 in upper tract urothelial carcinoma (UTUC) remains unclear. We performed immunohistochemical analysis of 99 UTUC samples to evaluate the expression status of Trop-2 in patients with UTUC and analyze its association with clinical outcomes. Trop-2 was positive in 94 of the 99 UTUC samples, and high Trop-2 expression was associated with favorable progression-free survival (PFS) and cancer-specific survival (<i>p</i> = 0.0011, 0.0046). Multivariate analysis identified high Trop-2 expression as an independent predictor of favorable PFS (all cases, <i>p</i> = 0.045; high-risk group (pT3≤ or presence of lymphovascular invasion or lymph node metastasis), <i>p</i> = 0.014). Gene expression analysis using RNA sequencing data from 72 UTUC samples demonstrated the association between high <i>TACSTD2</i> expression and favorable PFS (all cases, <i>p</i> = 0.069; high-risk group, <i>p</i> = 0.029). In conclusion, we demonstrated that Trop-2 is widely expressed in UTUC. Although high Trop-2 expression was a favorable prognostic factor in UTUC, its widespread expression suggests that sacituzumab govitecan may be effective for a wide range of UTUC.https://www.mdpi.com/1718-7729/29/6/312trophoblast cell surface antigen 2<i>TACSTD2</i>upper tract urothelial carcinomaimmunohistochemical analysisRNA sequencingsacituzumab govitecan |
| spellingShingle | Eisuke Tomiyama Kazutoshi Fujita Kosuke Nakano Ken Kuwahara Takafumi Minami Taigo Kato Koji Hatano Atsunari Kawashima Motohide Uemura Tetsuya Takao Hiroaki Fushimi Kotoe Katayama Seiya Imoto Kazuhiro Yoshimura Ryoichi Imamura Hirotsugu Uemura Norio Nonomura Trop-2 in Upper Tract Urothelial Carcinoma Current Oncology trophoblast cell surface antigen 2 <i>TACSTD2</i> upper tract urothelial carcinoma immunohistochemical analysis RNA sequencing sacituzumab govitecan |
| title | Trop-2 in Upper Tract Urothelial Carcinoma |
| title_full | Trop-2 in Upper Tract Urothelial Carcinoma |
| title_fullStr | Trop-2 in Upper Tract Urothelial Carcinoma |
| title_full_unstemmed | Trop-2 in Upper Tract Urothelial Carcinoma |
| title_short | Trop-2 in Upper Tract Urothelial Carcinoma |
| title_sort | trop 2 in upper tract urothelial carcinoma |
| topic | trophoblast cell surface antigen 2 <i>TACSTD2</i> upper tract urothelial carcinoma immunohistochemical analysis RNA sequencing sacituzumab govitecan |
| url | https://www.mdpi.com/1718-7729/29/6/312 |
| work_keys_str_mv | AT eisuketomiyama trop2inuppertracturothelialcarcinoma AT kazutoshifujita trop2inuppertracturothelialcarcinoma AT kosukenakano trop2inuppertracturothelialcarcinoma AT kenkuwahara trop2inuppertracturothelialcarcinoma AT takafumiminami trop2inuppertracturothelialcarcinoma AT taigokato trop2inuppertracturothelialcarcinoma AT kojihatano trop2inuppertracturothelialcarcinoma AT atsunarikawashima trop2inuppertracturothelialcarcinoma AT motohideuemura trop2inuppertracturothelialcarcinoma AT tetsuyatakao trop2inuppertracturothelialcarcinoma AT hiroakifushimi trop2inuppertracturothelialcarcinoma AT kotoekatayama trop2inuppertracturothelialcarcinoma AT seiyaimoto trop2inuppertracturothelialcarcinoma AT kazuhiroyoshimura trop2inuppertracturothelialcarcinoma AT ryoichiimamura trop2inuppertracturothelialcarcinoma AT hirotsuguuemura trop2inuppertracturothelialcarcinoma AT noriononomura trop2inuppertracturothelialcarcinoma |